Tumor Targeting by α_vβ₃-Integrin-Specific Lipid Nanoparticles Occurs via Phagocyte Hitchhiking.

ABSTRACT: Although the first nanomedicine was clinically approved more than two decades ago, nanoparticles' (NP) in vivo behavior is complex and the immune system's role in their application remains elusive. At present, only passive-targeting nanoformulations have been clinically approved, while more complicated active-targeting strategies typically fail to advance from the early clinical phase stage. This absence of clinical translation is, among others, due to the very limited understanding for in vivo targeting mechanisms. Dynamic in vivo phenomena such as NPs' real-time targeting kinetics and phagocytes' contribution to active NP targeting remain largely unexplored. To better understand in vivo targeting, monitoring NP accumulation and distribution at complementary le

SUBMITTER: Sofias AM 

PROVIDER: S-EPMC7392528 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature